

#RESEARCHNEVERSTOPS

Evotec Gene Therapy

RNA/DNA/LNP capabilities



Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.



Evotec GT¹ – Adding value to our partners' research

Innovative and flexible solutions from target identification to clinical candidates

The people

- Outstanding scientists
- Strong experience in gene therapy and drug development for rare diseases
- Poised to progress pipeline assets into clinic



Therapeutic area expertise

• Team leverages therapeutic area insights from years of industry experience and across Evotec



Integrated drug discovery & development

- State-of-the-art capabilities
- Best-in-class technology platforms

Flexible deal structures

• Integrated collaborations and stand-alone services



A gene therapy platform combined with world-class drug discovery & development expertise to accelerate and maximize our partners' success



Leadership A team of experts

Friedrich Scheiflinger EVP, General Manager Gene Therapy >30 years Academia and Pharma Hematology, Immunology. Rare Diseases, Metabolic diseases, LSD's / IEM.	Hanspeter Rottensteiner SVP, Head <i>In vitro</i> Gene therapy >20 years Academia and Pharma Gene expression and regulation, Cell Biology, Rare Diseases, Hematology	F	Werner Höllriegl VP, Head <i>In vivo</i> Gene therapy >20 years Pharma <i>In vivo</i> Translational Research, Nonclinical Development, Rare Diseases		Georg Feichtinger Lead Vectorology >15 years Academia and Entrepreneurship Synthetic biology, Gene expression & delivery, Musculoskeletal diseases, Regenerative medicine	(1: B)
TSRI, Immuno AG, Baxter Int., Baxalta, Shire, Takeda	Baxter, Baxalta, Shire, Takeda		AstraZeneca, Novartis IBR, Baxter, Baxalta, Shire,	Takeda	Univ. of Leeds, UCL, Univ. of York, LBI Trauma, Ph	ycosera
Barbara Plaimauer Lead Biology >20 years Pharma Transgene Biology, Biochemical and cell-based assays, Rare diseases	Vera Schoft Sen. Res. Scientist Novel Technologies >15 years Academia and Contract Research Molecular Biology, Epigenetics, Genome editing		Helmut Glantschnig Lead In vivo Sciences >20 years Pharma Molecular Pharmacology, Preclinical Sciences, Musculoskeletal diseases		Eva Mihailovska Lead Novel Platform >15 years Academia and Pharma Molecular cell biology, Neuro-degenerative disease. Vaccine Dev. (non-clinical and clinical).	

Strong Track-Record

- Highly experienced teams spanning decades of expertise in biologics, gene therapy & gene-editing development
- Numerous development programs, patents, and applications in the biotech field
- Successful submission of three gene therapy IND applications, paving the way for clinical trial initiation



Evotec Gene Therapy – Technical expertise

Covering viral and non-viral transduction technology



Flexible deal structures for EVOgenes: Integrated collaborations & stand-alone services



Relative contribution of Evotec and the respective partner at each phase is mutually agreed on a project-by-project basis

Accelerate and maximize our partners' success

- mRNA
 - mRNA research grade expression
 - LNP delivery
- DNA transfection
 - LNP delivery

Early de-risking through addressing the translational gap

Unlocking the promise of gene therapy



Augmented EVT-GT services

Standard viral in vivo gene therapy development technologies are strongly augmented by readily available, highly innovative, in-house capabilities



RNA-targeted therapeutic modalities

Evotec GT utilizes mRNA to support latest industry applications

RNA drug design

- siRNA
- mRNA
 - Linear, saRNA, circRNA
- RNA editing
 - RNA guided

Packaging and Delivery Services

- Dendrimers
- Liposomes
- Nanoparticles
- Lipid, Polymeric, Metal core
- Physical delivery methods
- Biomimetics
 - VLP, Exosome, Ab

RNA-centric Analytics

- HT RNA-seq PanOmics
 - Proprietary AI/ML based PanHunter transcriptomics
- Customized quantitative & functional assays
- RNA stability testing
- *In-vitro* Tox/safety (2D/3D) prediction algorithms

In-vivo Sciences

- On/Off Target Cell screens
- Local &systemic routes of administration
- Biodistribution, Durability and Biopotency (In-life imaging)
- Immunological assays
- RNA- or protein-based
- In-vitro/In-vivo correlations

Definition of Therapeutic RNA strategy



Selection and Optimization of modality



Proprietary and customizable tools and methodology







Evotec GT Non-viral LNP Capabilities

Integrated preclinical drug development platform

Formulation & payloads



Production platforms & principles

Continuous Solvent-Antisolvent Precipitation



In vitro & in vivo testing





In vitro potency testing

In vivo PoC, kinetics, efficacy & biodistribution testing

Analytics & QC





DLS characterization Bioanalyzer platform (size distribution, PDI) (payload integrity & stability)







RNAse contamination

Encapsulation efficacy % API concentration

6 Endotoxin (LAL) assay



Georg Feichtinger, PhD Group Leader Vectorology, Evotec Gene Therapy Evotec Nucleic Acid Delivery Working Group Lead

+43 2212 3200-315 (Direct) +43 664 88822919 (Mobile) georg.feichtinger@evotec.com www.evotec.com

Evotec GT GmbH Uferstrasse 15 A-2304 Orth an der Donau (Austria)